{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T08:19:52Z","timestamp":1758269992864,"version":"3.40.5"},"reference-count":110,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MC"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Understanding the cognitive and behavioral aspects of Alzheimer's disease-\nrelated dementia is surely a sturdy task to deal with. In recent years, a broad search for novel\nanti-Alzheimer agents has been continuously conducted. The malfunctioning of various neurotransmitter\nsystems and the accumulation of abnormal proteins in the brain are the two key characteristics\nof this disorder. This is supported by a growing amount of evidence. Some Pharmacophoric\ngroups\/combinations exhibit potential neuroprotective activity.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>This study aims to compile the most recent and interesting target\/target combinations\/\npharmacophoric combinations to cure Alzheimer's disease. We concentrated our efforts to find the\nability of certain pharmacophoric elements to interfere with various enzymatic and\/or receptor systems\nor to work as neuroprotective agents. These pharmacophoric elements may be proved to be\npromising leads for future multi-target anti-Alzheimer drug discovery programs.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Result:<\/jats:title>\n<jats:p>Anticholinesterase drugs were mentioned as the best treatment thus far. Additionally, impairments\nin the serotonergic, GABAergic, noradrenergic, dopaminergic, and glutaminergic and a\nfew other pathways have all been linked to memory, speech, behavioral and other alterations in\nAlzheimer's disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>This includes the study of workable pharmacophoric groups\/combinations, receptors\/\nenzymatic systems and related hypotheses to find the promising therapeutic lead compounds\nwhich could work as future anti-Alzheimer drugs. We discuss future work that would improve our\nunderstanding of this Disease.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573406418666220815101124","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T07:38:57Z","timestamp":1661845137000},"page":"132-146","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Structural Scaffolds as Anti- Alzheimer Agents"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2042-8413","authenticated-orcid":true,"given":"Tyagi","family":"Alka","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Dr. Bhawana Sati , Banasthali Vidyapith , Rajasthan, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2963-128X","authenticated-orcid":true,"given":"Bhawana","family":"Sati","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Dr. Bhawana Sati , Banasthali Vidyapith , Rajasthan, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1657-811X","authenticated-orcid":true,"given":"Anurag","family":"Chaudhary","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical\nTechnology, Dr. Anurag , Meerut Institute of Engineering and Technology, Meerut Uttar-Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1017\/S135561771700100X","volume":"23","author":"Bondi M.W.","year":"2017","unstructured":"Bondi M.W.; Edmonds E.C.; Salmon D.P.; Alzheimer\u2019s disease: Past, present, and future. J Int Neuropsychol Soc 2017,23(9-10),818-831","journal-title":"J Int Neuropsychol Soc"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0197-4580(98)00052-9","volume":"19","author":"Berchtold N.C.","year":"1998","unstructured":"Berchtold N.C.; Cotman C.W.; Evolution in the conceptualization of dementia and Alzheimer\u2019s disease: Greco-Roman period to the 1960s. Neurobiol Aging 1998,19(3),173-189","journal-title":"Neurobiol Aging"},{"key":"ref=3","first-page":"371","volume":"8","author":"Porsteinsson A.P.","year":"2021","unstructured":"Porsteinsson A.P.; Isaacson R.S.; Knox S.; Sabbagh M.N.; Rubino I.; Diagnosis of early Alzheimer\u2019s disease: Clinical practice in 2021. J Prev Alzheimers Dis 2021,8(3),371-386","journal-title":"J Prev Alzheimers Dis"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/ca.980080612","volume":"8","author":"Alzheimer A.","year":"1995","unstructured":"Alzheimer A.; Stelzmann R.A.; Schnitzlein H.N.; Murtagh F.R.; An english translation of Alzheimer\u2019s 1907 paper, &#x201C;Uber eine eigenartige Erkankung der Hirnrinde&#x201D;. Clin Anat 1995,8(6),429-431","journal-title":"Clin Anat"},{"key":"ref=5","first-page":"24","volume":"04","author":"Korolev I.O.","year":"2014","unstructured":"Korolev I.O.; Alzheimer s disease A clinical and basic science review. Med Student Res J 2014,04(September),24-33","journal-title":"Med Student Res J"},{"key":"ref=6","author":"Gilman S.","year":"2010","unstructured":"Gilman S.;  Oxford American Handbook of Neurology 2010","journal-title":"Oxford American Handbook of Neurology"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/0028-3932(95)00046-1","volume":"33","author":"Greene J.D.W.","year":"1995","unstructured":"Greene J.D.W.; Hodges J.R.; Baddeley A.D.; Autobiographical memory and executive function in early dementia of Alzheimer type. Neuropsychologia 1995,33(12),1647-1670","journal-title":"Neuropsychologia"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1037\/0033-295X.85.3.139","volume":"85","author":"Baddeley A.D.","year":"1978","unstructured":"Baddeley A.D.; The trouble with levels: A re-examination of Craik and Lockhart\u2019s framework for memory research. Psychol Rev 1978,85(3),139-152","journal-title":"Psychol Rev"},{"key":"ref=9","first-page":"649","volume":"5","author":"Khan M.M.","year":"2016","unstructured":"Khan M.M.; Ahsan F.; Ahmad U.; Akhtar J.; Badruddeen; Mujahid, M. Alzheimer disease: A review. World J Pharm Pharm Sci 2016,5(June),649-666","journal-title":"World J Pharm Pharm Sci"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000109998","volume":"29","author":"Plassman B.L.","year":"2007","unstructured":"Plassman B.L.; Langa K.M.; Fisher G.G.; Heeringa S.G.; Weir D.R.; Ofstedal M.B.; Burke J.R.; Hurd M.D.; Potter G.G.; Rodgers W.L.; Steffens D.C.; Willis R.J.; Wallace R.B.; Prevalence of dementia in the United States: The aging, demographics, and memory study. Neuroepidemiology 2007,29(1-2),125-132","journal-title":"Neuroepidemiology"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jalz.2013.02.003","volume":"9","author":"Association A.","year":"2013","unstructured":"Association A.; 2013 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 2013,9(2),208-245","journal-title":"Alzheimers Dement"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","volume":"9","author":"Prince M.","year":"2013","unstructured":"Prince M.; Bryce R.; Albanese E.; Wimo A.; Ribeiro W.; Ferri C.P.; The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement 2013,9(1),63-75.e2","journal-title":"Alzheimers Dement"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/bmj.310.6985.970","volume":"310","author":"Ott A.","year":"1995","unstructured":"Ott A.; Breteler M.M.; van Harskamp F.; Claus J.J.; van der Cammen T.J.; Grobbee D.E.; Hofman A.; Prevalence of Alzheimer\u2019s disease and vascular dementia: Association with education. The Rotterdam study. BMJ 1995,310(6985),970-973","journal-title":"BMJ"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1126\/science.1074069","volume":"298","author":"Selkoe D.J.","year":"2002","unstructured":"Selkoe D.J.; Alzheimer\u2019s disease is a synaptic failure. Science 2002,298(5594),789-791","journal-title":"Science"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules26185527","volume":"26","author":"Bachurin S.O.","year":"2021","unstructured":"Bachurin S.O.; Makhaeva G.F.; Shevtsova E.F.; Aksinenko A.Y.; Grigoriev V.V.; Shevtsov P.N.; Goreva T.V.; Epishina T.A.; Kovaleva N.V.; Pushkareva E.A.; Boltneva N.P.; Lushchekina S.V.; Gabrelyan A.V.; Zamoyski V.L.; Dubova L.G.; Rudakova E.V.; Fisenko V.P.; Bovina E.V.; Richardson R.J.; Conjugation of aminoadamantane and &#x3B3;-carboline pharmacophores gives rise to unexpected properties of multifunctional ligands. Molecules 2021,26(5527),1-26","journal-title":"Molecules"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"Long J.M.","year":"2019","unstructured":"Long J.M.; Holtzman D.M.; Alzheimer disease: An update on pathobiology and treatment strategies. Cell 2019,179(2),312-339","journal-title":"Cell"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jalz.2010.11.002","volume":"7","author":"Rocca W.A.","year":"2011","unstructured":"Rocca W.A.; Petersen R.C.; Knopman D.S.; Hebert L.E.; Evans D.A.; Hall K.S.; Gao S.; Unverzagt F.W.; Langa K.M.; Larson E.B.; White L.R.; Trends in the incidence and prevalence of Alzheimer\u2019s disease, dementia, and cognitive impairment in the United States. Alzheimers Dement 2011,7(1),80-93","journal-title":"Alzheimers Dement"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3934\/Neuroscience.2021005","volume":"8","author":"Calabr&#xF2; M.","year":"2020","unstructured":"Calabr&#xF2; M.; Rinaldi C.; Santoro G.; Crisafulli C.; The biological pathways of Alzheimer disease: A review. AIMS Neurosci 2020,8(1),86-132","journal-title":"AIMS Neurosci"},{"key":"ref=19","first-page":"84","volume":"86","author":"Brown T.","year":"2008","unstructured":"Brown T.; Design thinking. Harv Bus Rev 2008,86(6),84-92, 141","journal-title":"Harv Bus Rev"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1002\/med.21699","volume":"41","author":"Albertini C.","year":"2021","unstructured":"Albertini C.; Salerno A.; de Sena Murteira Pinheiro P.; Bolognesi M.L.; From combinations to multitarget-directed ligands: A continuum in Alzheimer\u2019s disease polypharmacology. Med Res Rev 2021,41(5),2606-2633","journal-title":"Med Res Rev"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ejmech.2013.12.028","volume":"75","author":"Bautista-Aguilera O.M.","year":"2014","unstructured":"Bautista-Aguilera O.M.; Esteban G.; Bolea I.; Nikolic K.; Agbaba D.; Moraleda I.; Iriepa I.; Samadi A.; Soriano E.; Unzeta M.; Marco-Contelles J.; Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase\/monoamine oxidase inhibitors for the potential treatment of Alzheimer\u2019s disease. Eur J Med Chem 2014,75,82-95","journal-title":"Eur J Med Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.bmc.2010.12.022","volume":"19","author":"Luo W.","year":"2011","unstructured":"Luo W.; Li Y-P.; He Y.; Huang S-L.; Tan J-H.; Ou T-M.; Li D.; Gu L-Q.; Huang Z-S.; Design, synthesis and evaluation of novel tacrine-multialkoxybenzene hybrids as dual inhibitors for cholinesterases and amyloid beta aggregation. Bioorg Med Chem 2011,19(2),763-770","journal-title":"Bioorg Med Chem"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1006\/exnr.2000.7397","volume":"163","author":"Bartus R.T.","year":"2000","unstructured":"Bartus R.T.; On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000,163(2),495-529","journal-title":"Exp Neurol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.neuroscience.2012.12.054","volume":"234","author":"Reid G.A.","year":"2013","unstructured":"Reid G.A.; Chilukuri N.; Darvesh S.; Butyrylcholinesterase and the cholinergic system. Neuroscience 2013,234,53-68","journal-title":"Neuroscience"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1471-4159.1983.tb11311.x","volume":"40","author":"Sims N.R.","year":"1983","unstructured":"Sims N.R.; Bowen D.M.; Allen S.J.; Smith C.C.T.; Neary D.; Thomas D.J.; Davison A.N.; Presynaptic cholinergic dysfunction in patients with dementia. J Neurochem 1983,40(2),503-509","journal-title":"J Neurochem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.ejmech.2013.03.051","volume":"64","author":"Xie S.S.","year":"2013","unstructured":"Xie S.S.; Wang X.B.; Li J.Y.; Yang L.; Kong L.Y.; Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer\u2019s disease. Eur J Med Chem 2013,64,540-553","journal-title":"Eur J Med Chem"},{"key":"ref=27","first-page":"1","volume":"4e-2140","author":"Chen Y.","year":"2016","unstructured":"Chen Y.; Bian Y.; Sun Y.; Kang C.; Yu S.; Fu T.; Li W.; Pei Y.; Sun H.;  Identification of 4-aminoquinoline core for the design of new cholinesterase inhibitors. Peer J. 2016,4e-2140(7),1-15"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1358\/mf.2000.22.8.701373","volume":"22","author":"Ogura H.","year":"2000","unstructured":"Ogura H.; Kosasa T.; Kuriya Y.; Yamanishi Y.; Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find Exp Clin Pharmacol 2000,22(8),609-613","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2165\/00023210-199912040-00005","volume":"12","author":"Weinstock M.","year":"1999","unstructured":"Weinstock M.; Selectivity of cholinesterase inhibition: Clinical implications for the treatment of Alzheimer\u2019s disease. CNS Drugs 1999,12(4),307-323","journal-title":"CNS Drugs"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules24030587","volume":"24","author":"Rajeshwari R.","year":"2019","unstructured":"Rajeshwari R.; Chand K.; Candeias E.; Cardoso S.M.; Chaves S.; Santos M.A.; New multitarget hybrids bearing tacrine and phenylbenzothiazole motifs as potential drug candidates for Alzheimer\u2019s disease. Molecules 2019,24(3),1-15","journal-title":"Molecules"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1021\/bi020016x","volume":"41","author":"Bar-On P.","year":"2002","unstructured":"Bar-On P.; Millard C.B.; Harel M.; Dvir H.; Enz A.; Sussman J.L.; Silman I.; Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. Biochemistry 2002,41(11),3555-3564","journal-title":"Biochemistry"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1034\/j.1600-0404.2000.00311.x","volume":"176","author":"Greig N.H.","year":"2000","unstructured":"Greig N.H.; De Micheli E.; Holloway H.W.; Yu Q.S.; Utsuki T.; Perry T.A.; Brossi A.; Ingram D.K.; Deutsch J.; Lahiri D.K.; Soncrant T.T.; The experimental Alzheimer drug phenserine: Preclinical pharmacokinetics and pharmacodynamics. Acta Neurol Scand Suppl 2000,176,74-84","journal-title":"Acta Neurol Scand Suppl"},{"key":"ref=33","first-page":"1087","volume":"19","year":"1996","unstructured":"Adams, J. Drug Evaluation. Aust Prescr 1996,19(1),1087-1097","journal-title":"Aust Prescr"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0009-2797(99)00020-4","volume":"119-120","author":"Simeon-Rudolf V.","year":"1999","unstructured":"Simeon-Rudolf V.; Kovarik Z.; Radi\u0107 Z.; Reiner, E. Reversible inhibition of acetylcholinesterase and butyrylcholinesterase by 4,4-bipyridine and by a coumarin derivative. Chem Biol Interact 1999,119-120,119-128","journal-title":"Chem Biol Interact"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"11233","DOI":"10.1016\/S0021-9258(19)78115-0","volume":"269","year":"1994","unstructured":"Radi\u0107 Z.; Duran, R.; Vellom, D.C.; Li, Y.; Cervenansky, C.; Taylor, P. Site of fasciculin interaction with acetylcholinesterase. J Biol Chem 1994,269(15),11233-11239","journal-title":"J Biol Chem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1021\/jm0340602","volume":"46","author":"Piazzi L.","year":"2003","unstructured":"Piazzi L.; Rampa A.; Bisi A.; Gobbi S.; Belluti F.; Cavalli A.; Bartolini M.; Andrisano V.; Valenti P.; Recanatini M.; 3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced &#x3B2;-amyloid aggregation: A dual function lead for Alzheimers disease therapy. J Med Chem 2003,46(12),2279-2282","journal-title":"J Med Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1021\/jm070100g","volume":"50","author":"Piazzi L.","year":"2007","unstructured":"Piazzi L.; Cavalli A.; Belluti F.; Bisi A.; Gobbi S.; Rizzo S.; Bartolini M.; Andrisano V.; Recanatini M.; Rampa A.; Brief Articles. J Med Chem 2007,50(17),4250-4254","journal-title":"J Med Chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.bmc.2010.01.071","volume":"18","author":"Rizzo S.","year":"2010","unstructured":"Rizzo S.; Bartolini M.; Ceccarini L.; Piazzi L.; Gobbi S.; Cavalli A.; Recanatini M.; Andrisano V.; Rampa A.; Targeting Alzheimer\u2019s disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238. Bioorg Med Chem 2010,18(5),1749-1760","journal-title":"Bioorg Med Chem"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1021\/jm8001313","volume":"51","author":"Camps P.","year":"2008","unstructured":"Camps P.; Formosa X.; Galdeano C.; G&#xF3;mez T.; Mu&#xF1;oz-Torrero D.; Scarpellini M.; Viayna E.; Badia A.; Clos M.V.; Camins A.; Pall&#xE0;s M.; Bartolini M.; Mancini F.; Andrisano V.; Estelrich J.; Lizondo M.; Bidon-Chanal A.; Luque F.J.; Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced &#x3B2;-amyloid aggregation. J Med Chem 2008,51(12),3588-3598","journal-title":"J Med Chem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.1021\/jm060164b","volume":"49","author":"Rydberg E.H.","year":"2006","unstructured":"Rydberg E.H.; Brumshtein B.; Greenblatt H.M.; Wong D.M.; Shaya D.; Williams L.D.; Carlier P.R.; Pang Y.P.; Silman I.; Sussman J.L.; Complexes of alkylene-linked tacrine dimers with Torpedo californica acetylcholinesterase: Binding of Bis5-tacrine produces a dramatic rearrangement in the active-site gorge. J Med Chem 2006,49(18),5491-5500","journal-title":"J Med Chem"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cbi.2019.05.024","volume":"308","author":"Bosak A.","year":"2019","unstructured":"Bosak A.; Opsenica D.M.; \u0160inko G.; Zlatar M.; Kovarik Z.; Structural aspects of 4-aminoquinolines as reversible inhibitors of human acetylcholinesterase and butyrylcholinesterase. Chem Biol Interact 2019,308(March),101-109","journal-title":"Chem Biol Interact"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"7856","DOI":"10.1021\/ja7109822","volume":"130","author":"Harel M.","year":"2008","unstructured":"Harel M.; Sonoda L.K.; Silman I.; Sussman J.L.; Rosenberry T.L.; Crystal structure of thioflavin T bound to the peripheral site of Torpedo californica acetylcholinesterase reveals how thioflavin T acts as a sensitive fluorescent reporter of ligand binding to the acylation site. J Am Chem Soc 2008,130(25),7856-7861","journal-title":"J Am Chem Soc"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ejmech.2014.05.056","volume":"82","author":"Alipour M.","year":"2014","unstructured":"Alipour M.; Khoobi M.; Moradi A.; Nadri H.; Homayouni Moghadam F.; Emami S.; Hasanpour Z.; Foroumadi A.; Shafiee A.; Synthesis and anti-cholinesterase activity of new 7-hydroxycoumarin derivatives. Eur J Med Chem 2014,82,536-544","journal-title":"Eur J Med Chem"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ejmech.2013.07.045","volume":"68","author":"Khoobi M.","year":"2013","unstructured":"Khoobi M.; Alipour M.; Moradi A.; Sakhteman A.; Nadri H.; Razavi S.F.; Ghandi M.; Foroumadi A.; Shafiee A.; Design, synthesis, docking study and biological evaluation of some novel tetrahydrochromeno [3\u20324\u20325,6]pyrano[2,3-b]quinolin-6(7H)-one derivatives against acetyl- and butyrylcholinesterase. Eur J Med Chem 2013,68,291-300","journal-title":"Eur J Med Chem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ejmech.2013.03.021","volume":"64","author":"Razavi S.F.","year":"2013","unstructured":"Razavi S.F.; Khoobi M.; Nadri H.; Sakhteman A.; Moradi A.; Emami S.; Foroumadi A.; Shafiee A.; Synthesis and evaluation of 4-substituted coumarins as novel acetylcholinesterase inhibitors. Eur J Med Chem 2013,64,252-259","journal-title":"Eur J Med Chem"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1111\/cbdd.12588","volume":"86","author":"Bagheri S.M.","year":"2015","unstructured":"Bagheri S.M.; Khoobi M.; Nadri H.; Moradi A.; Emami S.; Jalili-Baleh L.; Jafarpour F.; Homayouni Moghadam F.; Foroumadi A.; Shafiee A.; Synthesis and anticholinergic activity of 4-hydroxycoumarin derivatives containing substituted benzyl-1,2,3-triazole moiety. Chem Biol Drug Des 2015,86(5),1215-1220","journal-title":"Chem Biol Drug Des"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/(SICI)1099-1166(199901)14:1<3:AID-GPS897>3.0.CO;2-7","volume":"14","author":"Cacabelos R.","year":"1999","unstructured":"Cacabelos R.; Takeda M.; Winblad B.; The glutamatergic system and neurodegeneration in dementia: Preventive strategies in Alzheimers disease. Int J Geriatr Psychiatry 1999,14(1),3-47","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=48","first-page":"718","volume":"64","author":"Sokolov V.B.","year":"2015","unstructured":"Sokolov V.B.; Aksinenko A.Y.; Epishina T.A.; Goreva T.V.; Grigoriev V.V.; Gabrel A.V.; Bachurin S.O.; Synthesis and biological activity of N substituted tetrahydro &#x3B3;-carbolins bearing bis ( dimethylamino ) phenothiazine moiety. Russ. Chemical. Bull., International Edition, 2015,64(3),718-722"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/ph7020113","volume":"7","author":"Zheng H.","year":"2014","unstructured":"Zheng H.; Fridkin M.; Youdim M.; From single target to multitarget\/network therapeutics in Alzheimer\u2019s therapy. Pharmaceuticals (Basel) 2014,7(2),113-135","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s11172-014-0561-3","volume":"63","author":"Sokolov V.B.","year":"2014","unstructured":"Sokolov V.B.; Aksinenko A.Y.; Nikolaeva N.S.; Grigor\u2019ev V.V.; Kinzirsky A.S.; Bachurin S.O.; Modification of biologically active amides and amines with fluoro-containing heterocycles 11. tetrahydrocarbazoles modified with 2-(5-fluoropyridin-3-yl)ethyl fragment. Russ Chem Bull 2014,63(5),1137-1141","journal-title":"Russ Chem Bull"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1021\/jm7009364","volume":"51","author":"Cavalli A.","year":"2008","unstructured":"Cavalli A.; Bolognesi M.L.; Minarini A.; Rosini M.; Tumiatti V.; Recanatini M.; Melchiorre C.; Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 2008,51(3),347-372","journal-title":"J Med Chem"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1586\/ern.12.124","volume":"12","author":"Francis P.T.","year":"2012","unstructured":"Francis P.T.; Parsons C.G.; Jones R.W.; Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer\u2019s disease. Expert Rev Neurother 2012,12(11),1351-1365","journal-title":"Expert Rev Neurother"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.2174\/0929867311320130004","volume":"20","author":"Bolognesi M.L.","year":"2013","unstructured":"Bolognesi M.L.; Polypharmacology in a single drug: Multitarget drugs. Curr Med Chem 2013,20(13),1639-1645","journal-title":"Curr Med Chem"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1007\/s11172-016-1461-5","volume":"65","author":"Sokolov V.B.","year":"2016","unstructured":"Sokolov V.B.; Aksinenko A.Y.; Goreva T.V.; Epishina T.A.; Grigor\u2019ev V.V.; Gabrel\u2019yan A.V.; Vinogradova D.V.; Neganova M.E.; Shevtsova E.F.; Bachurin S.O.; Molecular design of multitarget neuroprotectors 3. Synthesis and bioactivity of tetrahydrocarbazole-aminoadamantane conjugates. Russ Chem Bull 2016,65(5),1354-1359","journal-title":"Russ Chem Bull"},{"key":"ref=55","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5120230","volume":"2020","author":"Maramai S.","year":"2020","unstructured":"Maramai S.; Benchekroun M.; Gabr M.T.; Yahiaoui S.; Multitarget therapeutic strategies for Alzheimer\u2019s disease: Review on emerging target combinations. BioMed Res Int 2020,2020","journal-title":"BioMed Res Int"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1016\/j.bmcl.2018.07.019","volume":"28","author":"Gabr M.T.","year":"2018","unstructured":"Gabr M.T.; Abdel-Raziq M.S.; Structure-based design, synthesis, and evaluation of structurally rigid donepezil analogues as dual AChE and BACE-1 inhibitors. Bioorg Med Chem Lett 2018,28(17),2910-2913","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ejmech.2019.07.051","volume":"180","author":"P&#xE9;rez-Areales F.J.","year":"2019","unstructured":"P&#xE9;rez-Areales F.J.; Turcu A.L.; Barniol-Xicota M.; Pont C.; Pivetta D.; Espargar&#xF3; A.; Bartolini M.; De Simone A.; Andrisano V.; P&#xE9;rez B.; Sabate R.; Sureda F.X.; V&#xE1;zquez S.; Mu&#xF1;oz-Torrero D.; A novel class of multitarget anti-Alzheimer benzohomoadamantane chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors. Eur J Med Chem 2019,180,613-626","journal-title":"Eur J Med Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.nbd.2005.09.004","volume":"21","author":"Emilsson L.","year":"2006","unstructured":"Emilsson L.; Saetre P.; Jazin E.; Alzheimer\u2019s disease: mRNA expression profiles of multiple patients show alterations of genes involved with calcium signaling. Neurobiol Dis 2006,21(3),618-625","journal-title":"Neurobiol Dis"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1073\/pnas.0813355106","volume":"106","author":"Diaz J.C.","year":"2009","unstructured":"Diaz J.C.; Simakova O.; Jacobson K.A.; Arispe N.; Pollard H.B.; Small molecule blockers of the Alzheimer abeta calcium channel potently protect neurons from abeta cytotoxicity. Proc Natl Acad Sci USA 2009,106(9),3348-3353","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.ejmech.2018.06.044","volume":"155","author":"Chioua M.","year":"2018","unstructured":"Chioua M.; Buzzi E.; Moraleda I.; Iriepa I.; Maj M.; Wnorowski A.; Giovannini C.; Tramarin A.; Portali F.; Ismaili L.; L&#xF3;pez-Alvarado P.; Bolognesi M.L.; J&#xF3;&#x17A;wiak, K.; Men&#xE9;ndez, J.C.; Marco-Contelles, J.; Bartolini, M. Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer\u2019s disease. Eur J Med Chem 2018,155,839-846","journal-title":"Eur J Med Chem"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.pharmthera.2005.05.001","volume":"108","author":"Mitchell E.S.","year":"2005","unstructured":"Mitchell E.S.; Neumaier J.F.; 5-HT6 receptors: A novel target for cognitive enhancement. Pharmacol Ther 2005,108(3),320-333","journal-title":"Pharmacol Ther"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1021\/acs.molpharmaceut.5b00830","volume":"13","author":"Ivachtchenko A.V.","year":"2016","unstructured":"Ivachtchenko A.V.; Lavrovsky Y.; Ivanenkov Y.A.; AVN-211, novel and highly selective 5-HT6 receptor small molecule antagonist, for the treatment of Alzheimer\u2019s disease. Mol Pharm 2016,13(3),945-963","journal-title":"Mol Pharm"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.bmc.2010.12.055","volume":"19","author":"Ivachtchenko A.V.","year":"2011","unstructured":"Ivachtchenko A.V.; Golovina E.S.; Kadieva M.G.; Kysil V.M.; Mitkin O.D.; Tkachenko S.E.; Okun I.; Synthesis and SAR of 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines as potent serotonin 5-HT6 receptor antagonists. Bioorg Med Chem 2011,19(4),1482-1491","journal-title":"Bioorg Med Chem"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3233\/JAD-151146","volume":"53","author":"Ivachtchenko A.V.","year":"2016","unstructured":"Ivachtchenko A.V.; Lavrovsky Y.; Okun I.; AVN-101: A multi-target drug candidate for the treatment of CNS disorders. J Alzheimers Dis 2016,53(2),583-620","journal-title":"J Alzheimers Dis"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules24214009","volume":"24","author":"Alsaedi A.M.R.","year":"2019","unstructured":"Alsaedi A.M.R.; Farghaly T.A.; Shaaban M.R.; Synthesis and antimicrobial evaluation of novel pyrazolopyrimidines incorporated with mono- and diphenylsulfonyl groups. Molecules 2019,24(21),1-21","journal-title":"Molecules"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1111\/j.1476-5381.1996.tb16086.x","volume":"119","author":"Blandina P.","year":"1996","unstructured":"Blandina P.; Giorgetti M.; Bartolini L.; Cecchi M.; Timmerman H.; Leurs R.; Pepeu G.; Giovannini M.G.; Inhibition of cortical acetylcholine release and cognitive performance by histamine H3 receptor activation in rats. Br J Pharmacol 1996,119(8),1656-1664","journal-title":"Br J Pharmacol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1016\/j.bmc.2007.12.048","volume":"16","author":"Bembenek S.D.","year":"2008","unstructured":"Bembenek S.D.; Keith J.M.; Letavic M.A.; Apodaca R.; Barbier A.J.; Dvorak L.; Aluisio L.; Miller K.L.; Lovenberg T.W.; Carruthers N.I.; Lead identification of acetylcholinesterase inhibitors-histamine H3 receptor antagonists from molecular modeling. Bioorg Med Chem 2008,16(6),2968-2973","journal-title":"Bioorg Med Chem"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"6446","DOI":"10.1021\/jm701225u","volume":"50","author":"Bolognesi M.L.","year":"2007","unstructured":"Bolognesi M.L.; Cavalli A.; Valgimigli L.; Bartolini M.; Rosini M.; Andrisano V.; Recanatini M.; Melchiorre C.; Multi-target-directed drug design strategy: From a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer\u2019s disease. J Med Chem 2007,50(26),6446-6449","journal-title":"J Med Chem"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"7158","DOI":"10.1016\/j.bmc.2011.09.061","volume":"19","author":"Huang W.","year":"2011","unstructured":"Huang W.; Tang L.; Shi Y.; Huang S.; Xu L.; Sheng R.; Wu P.; Li J.; Zhou N.; Hu Y.; Searching for the Multi-Target-Directed Ligands against Alzheimer\u2019s disease: Discovery of quinoxaline-based hybrid compounds with AChE, HR and BACE 1 inhibitory activities. Bioorg Med Chem 2011,19(23),7158-7167","journal-title":"Bioorg Med Chem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"10857","DOI":"10.1523\/JNEUROSCI.1738-05.2005","volume":"25","author":"Okamura N.","year":"2005","unstructured":"Okamura N.; Suemoto T.; Furumoto S.; Suzuki M.; Shimadzu H.; Akatsu H.; Yamamoto T.; Fujiwara H.; Nemoto M.; Maruyama M.; Arai H.; Yanai K.; Sawada T.; Kudo Y.; Quinoline and benzimidazole derivatives: Candidate probes for in vivo imaging of tau pathology in Alzheimer\u2019s disease. J Neurosci 2005,25(47),10857-10862","journal-title":"J Neurosci"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"15084","DOI":"10.1038\/s41598-021-94369-0","volume":"11","author":"Nash A.","year":"2021","unstructured":"Nash A.; Gijsen H.J.M.; Hrupka B.J.; Teng K.S.L.; Lichtenthaler S.F.; Takeshima H.; Gunnersen J.M.; Munro K.M.; BACE inhibitor treatment of mice induces hyperactivity in a Seizure-related gene 6 family dependent manner without altering learning and memory. Sci Rep 2021,11(1),15084","journal-title":"Sci Rep"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/13543784.2019.1683160","volume":"28","author":"Imbimbo B.P.","year":"2019","unstructured":"Imbimbo B.P.; Watling M.; Investigational BACE inhibitors for the treatment of Alzheimer\u2019s disease. Expert Opin Investig Drugs 2019,28(11),967-975","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/nm0103-3","volume":"9","author":"Yang L.","year":"2003","unstructured":"Yang L.; Lindholm K.; Yan R.; Citron M.; Xia W.; Yang X.; Beach T.; Sue L.; Wong P.; Price D.; Li R.; Shen Y.; Elevated  -secretase expression and enzymatic activity measuring t-cell \u2013 mediated cytotoxicity using antibody to activated caspase 3. Nat Med 2003,9(1),3-4","journal-title":"Nat Med"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s12031-016-0800-1","volume":"60","author":"Munro K.M.","year":"2016","unstructured":"Munro K.M.; Nash A.; Pigoni M.; Lichtenthaler S.F.; Gunnersen J.M.; Functions of the Alzheimer\u2019s disease protease BACE1 at the synapse in the central nervous system. J Mol Neurosci 2016,60(3),305-315","journal-title":"J Mol Neurosci"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"9307","DOI":"10.3390\/molecules19079307","volume":"19","author":"Saturnino C.","year":"2014","unstructured":"Saturnino C.; Iacopetta D.; Sinicropi M.S.; Rosano C.; Caruso A.; Caporale A.; Marra N.; Marengo B.; Pronzato M.A.; Parisi O.I.; Longo P.; Ricciarelli R.; N-alkyl carbazole derivatives as new tools for Alzheimer\u2019s disease: Preliminary studies. Molecules 2014,19(7),9307-9317","journal-title":"Molecules"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph12010041","volume":"12","author":"Maia M.A.","year":"2019","unstructured":"Maia M.A.; Sousa E.; BACE-1 and -secretase as therapeutic targets for Alzheimer\u2019s disease. Pharmaceuticals (Basel) 2019,12(1),1-31","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"Doody R.S.","year":"2013","unstructured":"Doody R.S.; Raman R.; Farlow M.; Iwatsubo T.; Vellas B.; Joffe S.; Kieburtz K.; He F.; Sun X.; Thomas R.G.; Aisen P.S.; Siemers E.; Sethuraman G.; Mohs R.; A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N Engl J Med 2013,369(4),341-350","journal-title":"N Engl J Med"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1001\/archneurol.2012.2194","volume":"69","author":"Coric V.","year":"2012","unstructured":"Coric V.; van Dyck C.H.; Salloway S.; Andreasen N.; Brody M.; Richter R.W.; Soininen H.; Thein S.; Shiovitz T.; Pilcher G.; Colby S.; Rollin L.; Dockens R.; Pachai C.; Portelius E.; Andreasson U.; Blennow K.; Soares H.; Albright C.; Feldman H.H.; Berman R.M.; Safety and tolerability of the -secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 2012,69(11),1430-1440","journal-title":"Arch Neurol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/iub.1104","volume":"64","author":"Bollen E.","year":"2012","unstructured":"Bollen E.; Prickaerts J.; Phosphodiesterases in neurodegenerative disorders. IUBMB Life 2012,64(12),965-970","journal-title":"IUBMB Life"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1152\/physrev.1995.75.4.725","volume":"75","author":"Beavo J.A.","year":"1995","unstructured":"Beavo J.A.; Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 1995,75(4),725-748","journal-title":"Physiol Rev"},{"key":"ref=81","first-page":"150","volume":"59","author":"Uthayathas S.","year":"2007","unstructured":"Uthayathas S.; Karuppagounder S.S.; Thrash B.M.; Parameshwaran K.; Suppiramaniam V.; Dhanasekaran M.; Versatile effects of sildenafil: Recent pharmacological applications. Pharmacol Rep 2007,59(2),150-163","journal-title":"Pharmacol Rep"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.brainresbull.2019.09.001","volume":"153","author":"Liu L.","year":"2019","unstructured":"Liu L.; Xu H.; Ding S.; Wang D.; Song G.; Huang X.; Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer\u2019s disease. Brain Res Bull 2019,153,223-231","journal-title":"Brain Res Bull"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ejmech.2012.12.009","volume":"60","author":"Fiorito J.","year":"2013","unstructured":"Fiorito J.; Saeed F.; Zhang H.; Staniszewski A.; Feng Y.; Francis Y.I.; Rao S.; Thakkar D.M.; Deng S.X.; Landry D.W.; Arancio O.; Synthesis of quinoline derivatives: Discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer\u2019s disease. Eur J Med Chem 2013,60,285-294","journal-title":"Eur J Med Chem"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.crci.2017.07.009","volume":"20","author":"Nguyen M.","year":"2017","unstructured":"Nguyen M.; Huang M.; Liu Y.; Meunier B.; Robert A.; Is iron associated with amyloid involved in the oxidative stress of Alzheimer\u2019s disease? C R Chim 2017,20(11\u201312),987-989","journal-title":"C R Chim"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.crci.2018.01.005","volume":"21","author":"Zhang W.","year":"2018","unstructured":"Zhang W.; Huang M.; Bijani C.; Liu Y.; Robert A.; Meunier B.; Synthesis and characterization of copper-specific tetradendate ligands as potential treatment for Alzheimer\u2019s disease. Chem Rep 2018,21(5),475-483","journal-title":"Chem Rep"},{"key":"ref=86","first-page":"117","volume":"9","author":"Ye J.","year":"2005","unstructured":"Ye J.; Zhai H.Z.; Oxidative stress and Alzheimer disease. Zhongguo Linchuang Kangfu 2005,9(33),117-119","journal-title":"Zhongguo Linchuang Kangfu"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/39321","volume":"389","author":"Wyss-Coray T.","year":"1997","unstructured":"Wyss-Coray T.; Masliah E.; Mallory M.; McConlogue L.; Johnson-Wood K.; Lin C.; Mucke L.; Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer\u2019s disease. Nature 1997,389(6651),603-606","journal-title":"Nature"},{"key":"ref=88","first-page":"147","volume":"23","author":"Harman D.","year":"2000","unstructured":"Harman D.; Alzheimer\u2019s disease: A hypothesis on pathogenesis. J Am Aging Assoc 2000,23(3),147-161","journal-title":"J Am Aging Assoc"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"7787","DOI":"10.1073\/pnas.91.16.7787","volume":"91","author":"Yan S.D.","year":"1994","unstructured":"Yan S.D.; Chen X.; Schmidt A.M.; Brett J.; Godman G.; Zou Y.S.; Scott C.W.; Caputo C.; Frappier T.; Smith M.A.; Perry G.; Yen S.H.; Stern D.; Glycated tau protein in Alzheimer disease: A mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 1994,91(16),7787-7791","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1523\/JNEUROSCI.17-08-02653.1997","volume":"17","author":"Smith M.A.","year":"1997","unstructured":"Smith M.A.; Richey Harris P.L.; Sayre L.M.; Beckman J.S.; Perry G.; Widespread peroxynitrite-mediated damage in Alzheimer\u2019s disease. J Neurosci 1997,17(8),2653-2657","journal-title":"J Neurosci"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1073\/pnas.92.5.1794e","volume":"92","author":"Smith M.A.","year":"1995","unstructured":"Smith M.A.; Taneda S.; Richey P.L.; Miyata S.; Yant S.; Sternt D.; Sayre L.M.; Monnier V.M.; Perry G.; Advanced maillard reaction end products are associated with Alzheimer disease Pathology. Proc Natl Acad Sci USA 1995,92(5),1794-1794","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"Hardy J.","year":"2002","unstructured":"Hardy J.; Selkoe D.J.; The amyloid hypothesis of Alzheimer\u2019s disease: Progress and problems on the road to therapeutics. Science 2002,297(5580),353-356","journal-title":"Science"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1471-4159.2004.02743.x","volume":"91","author":"Gasparini L.","year":"2004","unstructured":"Gasparini L.; Ongini E.; Wenk G.; Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer\u2019s disease: Old and new mechanisms of action. J Neurochem 2004,91(3),521-536","journal-title":"J Neurochem"},{"key":"ref=94","first-page":"49","volume":"10","author":"Amr A.E.","year":"2000","unstructured":"Amr A.E.; Synthesis of some heterocyclic compounds as potential antimicrobial agents using 2,6-diacetylpyridine as synthon, n. Indian J Heterocycl Chem 2000,10,49-56","journal-title":"Indian J Heterocycl Chem"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ijbiomac.2012.04.012","volume":"51","author":"Abdalla M.M.","year":"2012","unstructured":"Abdalla M.M.; Al-Omar M.A.; Al-Salahi R.A.; Amr A.G.E.; Sabrye N.M.; A new investigation for some steroidal derivatives as anti-Alzheimer agents. Int J Biol Macromol 2012,51(1-2),56-63","journal-title":"Int J Biol Macromol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/cbf.290040202","volume":"4","author":"Tipton K.F.","year":"1986","unstructured":"Tipton K.F.; Enzymology of monoamine oxidase. Cell Biochem Funct 1986,4(2),79-87","journal-title":"Cell Biochem Funct"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrn1883","volume":"7","author":"Youdim M.B.H.","year":"2006","unstructured":"Youdim M.B.H.; Edmondson D.; Tipton K.F.; The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 2006,7(4),295-309","journal-title":"Nat Rev Neurosci"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00702-003-0828-6","volume":"110","author":"Kennedy B.P.","year":"2003","unstructured":"Kennedy B.P.; Ziegler M.G.; Alford M.; Hansen L.A.; Thal L.J.; Masliah E.; Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer\u2019s disease. J Neural Transm (Vienna) 2003,110(7),789-801","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nchembio0215-172c","volume":"11","author":"Narayan P.","year":"2015","unstructured":"Narayan P.; Ehsani S.; Lindquist S.; Erratum: Combating neurodegenerative disease with chemical probes and model systems. Nat Chem Biol 2015,11(2),172","journal-title":"Nat Chem Biol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"S287","DOI":"10.1038\/sj.bjp.0706464","volume":"147","author":"Youdim M.B.H.","year":"2006","unstructured":"Youdim M.B.H.; Bakhle Y.S.; Monoamine oxidase: Isoforms and inhibitors in Parkinson\u2019s disease and depressive illness. Br J Pharmacol 2006,147(S1)(Suppl. 1),S287-S296","journal-title":"Br J Pharmacol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1021\/jm3015926","volume":"56","author":"Trippier P.C.","year":"2013","unstructured":"Trippier P.C.; Jansen Labby K.; Hawker D.D.; Mataka J.J.; Silverman R.B.; Target- and mechanism-based therapeutics for neurodegenerative diseases: Strength in numbers. J Med Chem 2013,56(8),3121-3147","journal-title":"J Med Chem"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1042\/bj0220968","volume":"22","author":"Hare M.L.","year":"1928","unstructured":"Hare M.L.; Tyramine oxidase: A new enzyme system in liver. Biochem J 1928,22(4),968-979","journal-title":"Biochem J"},{"key":"ref=103","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112787","volume":"206","author":"Manzoor S.","year":"2020","unstructured":"Manzoor S.; Hoda N.; A comprehensive review of monoamine oxidase inhibitors as anti-Alzheimer\u2019s disease agents: A review. Eur J Med Chem 2020,206","journal-title":"Eur J Med Chem"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fchem.2018.00041","volume":"6","author":"Rauhamaki P.A.","year":"2018","unstructured":"Rauhamaki P.A.; Postila S.; Niinivehmas S.; Kortet E.; Schildt M.P.; Manivannan E.M.; Ahinko, P.; Koskimies, N.; Nyberg, P. H.; E.Multamaki, M.; Pasanen, R.O.; Juvonen, H.; Raunio, J. H.; Pentikainen, O. T Structure-activity relationship analysis of 3- Phenylcoumarin-based monoamine oxidase B inhibitors. Front Chem 2018,6(March),1-18","journal-title":"Front Chem"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1080\/14756366.2019.1574297","volume":"34","author":"Yang J.","year":"2019","unstructured":"Yang J.; Zhang P.; Hu Y.; Liu T.; Sun J.; Wang X.; Synthesis and biological evaluation of 3-arylcoumarins as potential anti-Alzheimer\u2019s disease agents. J Enzyme Inhib Med Chem 2019,34(1),651-656","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ejmech.2019.07.031","volume":"180","author":"Zhang C.","year":"2019","unstructured":"Zhang C.; Yang K.; Yu S.; Su J.; Yuan S.; Han J.; Chen Y.; Gu J.; Zhou T.; Bai R.; Xie Y.; Design, synthesis and biological evaluation of hydroxypyridinone-coumarin hybrids as multimodal monoamine oxidase B inhibitors and iron chelates against Alzheimer\u2019s disease. Eur J Med Chem 2019,180,367-382","journal-title":"Eur J Med Chem"},{"key":"ref=107","first-page":"28","volume":"2","author":"Munda P.","year":"2015","unstructured":"Munda P.; State of the art: Alzheimer\u2019s disease. Mt Sinai Sch Med 2015,2,28-32","journal-title":"Mt Sinai Sch Med"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1212\/WNL.48.3.626","volume":"48","author":"Stewart W.F.","year":"1997","unstructured":"Stewart W.F.; Kawas C.; Corrada M.; Metter E.J.; Risk of Alzheimer\u2019s disease and duration of NSAID use. Neurology 1997,48(3),626-632","journal-title":"Neurology"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1212\/WNL.54.2.295","volume":"54","author":"Henderson V.W.","year":"2000","unstructured":"Henderson V.W.; Paganini-Hill A.; Miller B.L.; Elble R.J.; Reyes P.F.; Shoupe D.; McCleary C.A.; Klein R.A.; Hake A.M.; Farlow M.R.; Estrogen for Alzheimer\u2019s disease in women: Randomized, double-blind, placebo-controlled trial. Neurology 2000,54(2),295-301","journal-title":"Neurology"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/j.1532-5415.1996.tb01400.x","volume":"44","author":"Schmidt R.","year":"1996","unstructured":"Schmidt R.; Fazekas F.; Reinhart B.; Kapeller P.; Fazekas G.; Offenbacher H.; Eber B.; Schumacher M.; Freidl W.; Estrogen replacement therapy in older women: A neuropsychological and brain MRI study. J Am Geriatr Soc 1996,44(11),1307-1313","journal-title":"J Am Geriatr Soc"}],"container-title":["Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573406418666220815101124","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/207466\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573406418666220815101124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T12:47:36Z","timestamp":1679316456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/207466\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":110,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573406418666220815101124","relation":{},"ISSN":["1573-4064"],"issn-type":[{"type":"print","value":"1573-4064"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-03-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}